Merck & Co., Inc.'s Q1 2019 earnings call highlighted several strong points that are likely to have a positive impact on the stock price in the short term:

1. **Strong Revenue Growth**: Merck reported an 8% year-over-year increase in total company revenues, driven by significant growth in oncology, vaccines, and hospital and specialty products, particularly KEYTRUDA, which saw a 60% increase in sales[6|.
2. **International Momentum**: International sales, especially in China, showed robust growth, with a 67% year-over-year increase, driven by newly launched products. This international performance is expected to continue, with additional approvals and market expansions anticipated[6|.
3. **Pipeline Advances**: The company reported several key approvals and advancements in its pipeline, including new indications for KEYTRUDA, progress with LYNPARZA and LENVIMA, and upcoming PDUFA dates for several products. These developments suggest continued innovation and growth potential[6|.
4. **Raised Guidance**: Merck narrowed and raised its revenue and non-GAAP EPS guidance for 2019, indicating confidence in its operational performance and growth prospects[6|.
5. **Operational Efficiency**: The company emphasized its focus on resource allocation, efficiency, and moderate R&D growth, which is expected to contribute to margin expansion over time[6!).

Given these positive factors, including strong revenue growth, international momentum, pipeline advancements, and raised guidance, the stock is likely to experience a positive impact in the short term.

**Rating: 2**